Cargando…

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine

Better understanding of the biology of resistance to DNA methyltransferase (DNMT) inhibitors is required to identify therapies that can improve their efficacy for patients with high-risk myelodysplastic syndrome (MDS). CCRL2 is an atypical chemokine receptor that is upregulated in CD34(+) cells from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karantanos, Theodoros, Teodorescu, Patric, Arvanitis, Marios, Perkins, Brandy, Jain, Tania, DeZern, Amy E., Dalton, W. Brian, Christodoulou, Ilias, Paun, Bogdan C., Varadhan, Ravi, Esteb, Christopher, Rajkhowa, Trivikram, Bonifant, Challice, Gondek, Lukasz P., Levis, Mark J., Yegnasubramanian, Srinivasan, Ghiaur, Gabriel, Jones, Richard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Myelodysplastic Syndromes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316237/ https://www.ncbi.nlm.nih.gov/pubmed/36519323 http://dx.doi.org/10.3324/haematol.2022.281444

Ejemplares similares

The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia
por: Karantanos, Theodoros, et al.
Publicado: (2022)

Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry
por: Clichet, Valentin, et al.
Publicado: (2023)

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
por: Teichman, Jennifer, et al.
Publicado: (2022)

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes
por: Fischer, Melissa A., et al.
Publicado: (2022)

Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation
por: Muto, Tomoya, et al.
Publicado: (2023)

COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021)

Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer
por: Petrone, Giulia, et al.
Publicado: (2022)

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms
por: Badar, Talha, et al.
Publicado: (2023)

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes
por: Taran, Sachi Jain, et al.
Publicado: (2015)

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study
por: Savona, Michael R., et al.
Publicado: (2021)

High-risk MDS after HMAs
por: Adès, Lionel
Publicado: (2019)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019)

Immunogenicity of Covid-19 Vaccination in Subjects with Myelodysplastic Syndromes
por: Vidler, Jennifer, et al.
Publicado: (2021)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
por: Feld, Jonathan, et al.
Publicado: (2020)

Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation
por: Gondek, Lukasz P., et al.
Publicado: (2016)

Incidence and Burden of the Myelodysplastic Syndromes
por: Cogle, Christopher R.
Publicado: (2015)

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2017)

Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
por: Bejar, Rafael
Publicado: (2015)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology
por: Karantanos, Theodoros, et al.
Publicado: (2021)

Molecular Basis for CCRL2 Regulation of Leukocyte Migration
por: Schioppa, Tiziana, et al.
Publicado: (2020)

From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes
por: Saygin, Caner
Publicado: (2023)

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2022)

OsCCRL1 is Essential for Phenylpropanoid Metabolism in Rice Anthers
por: Zhang, Lisha, et al.
Publicado: (2023)

Atypical chemokine receptor CCRL2 is overexpressed in prostate cancer cells
por: Reyes, Niradiz, et al.
Publicado: (2019)

CCRL2 Modulates Physiological and Pathological Angiogenesis During Retinal Development
por: Ben Dhaou, Cyrine, et al.
Publicado: (2021)

Exploring CCRL2 chemerin binding using accelerated molecular dynamics
por: Bufano, Marianna, et al.
Publicado: (2022)

Signaling Properties of Chemerin Receptors CMKLR1, GPR1 and CCRL2
por: De Henau, Olivier, et al.
Publicado: (2016)

Expression of CCRL2 Inhibits Tumor Growth by Concentrating Chemerin and Inhibiting Neoangiogenesis
por: Al Delbany, Diana, et al.
Publicado: (2021)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
por: DeZern, A., et al.
Publicado: (2022)

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Weight change over five-year periods and number of components of the metabolic syndrome in a Dutch cohort
por: Bot, M., et al.
Publicado: (2010)

Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome
por: Jie, Kim E, et al.
Publicado: (2010)

Syndrome in Question()
por: Orasmo, Cínthia Rosane, et al.
Publicado: (2014)

Syndrome in Question()
por: Meireles, Sheila Itamara Ferreira do Couto, et al.
Publicado: (2014)

Syndrome in question*
por: Wu, Yinhua, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nm5hujqvs7ei4677nv3sa25lb5